ID   T143
AC   CVCL_C7W4
DR   GEO; GSM1499920
DR   GEO; GSM1499921
DR   GEO; GSM1499922
DR   Wikidata; Q123033599
RX   PubMed=27723895;
CC   Doubling time: 27.17 +- 0.97 hours (Note=At 6-11th passages), 16.12 +- 1.45 hours (Note=At 60-62th passages) (PubMed=27723895).
CC   Omics: Transcriptomics; Microarray.
CC   Derived from site: In situ; Eye, uvea; UBERON=UBERON_0001768.
ST   Source(s): PubMed=27723895
ST   Amelogenin: X
ST   D10S1248: 14,15
ST   D12S391: 20,21
ST   D19S433: 16,17,18
ST   D1S1656: 14,15,16.3
ST   D22S1045: 16
ST   D2S1338: 19,20
ST   D2S441: 12,15
ST   D6S1043: 11
ST   TH01: 7,9.3
DI   NCIt; C7712; Uveal melanoma
DI   ORDO; Orphanet_39044; Uveal melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   55Y
CA   Cancer cell line
DT   Created: 29-06-23; Last updated: 10-04-25; Version: 3
//
RX   PubMed=27723895; DOI=10.1167/iovs.16-19317;
RA   Mouriaux F., Zaniolo K., Bergeron M.-A., Weidmann C.,
RA   de la Fouchardiere A., Fournier F., Droit A., Morcos M.W.,
RA   Landreville S., Guerin S.L.;
RT   "Effects of long-term serial passaging on the characteristics and
RT   properties of cell lines derived from uveal melanoma primary
RT   tumors.";
RL   Invest. Ophthalmol. Vis. Sci. 57:5288-5301(2016).
//